JAZZ News and Press, Jazz Pharmaceuticals plc From 11/16/23

2023-11-16 20:59:03 ET Summary Baupost Group's 13F portfolio value decreased from $5.61B to $5.21B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty Media Sirius XM, Veritiv, Alphabet, and Fidelity National Information Services accounting for ~56% of...

2023-11-14 16:00:00 ET Summary Avadel Pharmaceuticals reported strong Q3 earnings for Lumryz, exceeding consensus estimates and demonstrating successful market launch. Avadel's strategic market positioning and focus on high-volume prescribers contribute to its strong market positi...

2023-11-14 05:40:42 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Call Transcript Jazz Pharmaceuticals plc 2023 Q3 - Results - Earnings Call Presentation Jazz Pharma: Playing The High Notes With Xywav Jazz Pharmaceuticals Q3...

Total Deal Value of Up to $770.5 million including Upfront Payment and Potential Milestone Payments Autifony Eligible to Receive Royalties on Future Net Sales Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical ...

2023-11-08 23:34:12 ET Call Start: 16:30 Call End: 17:52 Jazz Pharmaceuticals PLC (JAZZ) Q3 2023 Earnings Conference Call November 08, 2023, 16:30 ET Company Participants Robert Iannone - EVP & Global Head, Research & Development Kim Sablich - EVP &am...

2023-11-08 23:34:12 ET Fleetcor Technologies, Inc. (FLT) Q3 2023 Earnings Conference Call November 08, 2023, 17:30 ET Company Participants James Eglseder - Head, IR Ronald Clarke - Chairman, President & CEO Thomas Panther - CFO Conference Call Participa...

2023-11-08 16:12:15 ET More on Jazz Pharmaceuticals Jazz Pharma: Playing The High Notes With Xywav Jazz Pharmaceuticals Q3 2023 Earnings Preview Jazz Pharmaceuticals Q3 2023 Earnings Preview Seeking Alpha’s Quant Rating on Jazz Pharmaceuticals ...

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance PR Newswire – 3Q23 total revenues of $972 million – – Combined revenues from key growth drivers, Xywav ® , Epidiolex ® and Rylaze &#x...

Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...

Jazz Pharmaceuticals plc (JAZZ) is expected to report $4.21 for Q3 2023